Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance with significant revenue growth in key products like Hadlima and Vtama. Despite slight margin declines, positive developments in market expansion and strategic investments, such as in DTC and telehealth campaigns, are promising. The Q&A highlights confidence in overcoming challenges, with plans for growth and deleveraging. No negative guidance or major concerns were raised, and the optimistic outlook on product expansions and sales strategies suggests a likely positive stock price reaction in the short term.
Key Financial Performance
Revenue $1.6 billion for Q2 2025, down 1% at constant currency year-over-year. The decline was due to the loss of exclusivity of Atozet in the EU, partially offset by growth pillars and contributions from new assets.
Adjusted EBITDA $522 million for Q2 2025, representing a 32.7% margin. Year-to-date adjusted EBITDA is $1 billion or a 32.4% margin. Strength was due to favorability in adjusted gross margin, investment prioritization, and savings from restructuring programs.
Free Cash Flow $525 million before one-time costs in the first half of 2025, ahead of the prior year. This was driven by active cash cycle management, lower interest expense, and favorable timing of cash tax payments.
Debt Repayment $350 million of principal on long-term debt repaid in Q2 2025. This action is part of a strategy to reduce net leverage below 4x by year-end.
Women's Health Franchise Grew 2% at constant currency in Q2 2025 compared to Q2 2024. Fertility business grew 15% due to favorable year-over-year comparison and increased demand. Jada grew double digits, while Nexplanon declined 1% globally but grew 10% outside the U.S.
Biosimilars Hadlima generated almost $100 million year-to-date, up 68% year-over-year. Performance was driven by its strong clinical profile, interchangeability approval, and effective commercial strategy.
Vtama Revenue $31 million in Q2 2025, up 35% sequentially and 70% year-over-year. Growth was driven by increased prescriber adoption and improved access objectives.
Adjusted Gross Margin 61.7% for Q2 2025, slightly down from 62% in Q2 2024. The decrease was due to pricing pressures, partially offset by favorable foreign exchange impacts.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nexplanon: Sales declined 1% in constant currency in Q2 2025. U.S. revenue dropped 5%, while international sales grew 10%. Submission for FDA approval for a 5-year duration indication has been made, with a potential launch later this year.
Vtama: Revenue reached $31 million in Q2 2025, up 35% sequentially and 70% year-over-year. Significant progress in access objectives, aiming for 80% addressable population coverage by early 2026. Approved for pediatric use as young as 2 years old.
Hadlima: Generated nearly $100 million in revenue as of June 2025, up 68% year-over-year. Strong clinical profile and commercial strategy contributed to growth.
Jada: Achieved double-digit growth in Q2 2025. Used in nearly half of postpartum hemorrhage care situations in hospitals with high adoption rates.
Fertility Business: Grew 15% in Q2 2025 due to increased demand and favorable comparisons. Geographical expansion expected to drive high single-digit growth globally in 2025.
Henlius Products: Portfolio launch planned for late 2025, including a denosumab biosimilar in the U.S.
Restructuring Programs: Generated $200 million in operational savings in 2025. Focused on creating a fit-for-purpose organization.
Debt Reduction: Repaid $350 million in long-term debt in Q2 2025. Targeting net leverage below 4x by year-end and 3.5x by the end of 2026.
Capital Allocation: Increased retention ratio of free cash flow to prioritize debt repayment. Achieved gains from debt repurchase and restructuring.
Biosimilars Expansion: Added Tofidence to the portfolio and planning to launch Henlius products, strengthening the immunology market presence.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Loss of Exclusivity (LOE): The company faced a $60 million impact in Q2 2025 due to the loss of exclusivity of Atozet in Europe, which occurred in September 2024. This has resulted in a $120 million impact year-to-date, with further headwinds expected until Q4 2025.
Pricing Pressure: Pricing pressure from mature products like NuvaRing, Dulera, Renflexis, and Ontruzant, as well as mandatory pricing revisions in regional markets like Japan, has negatively impacted revenue.
Funding Constraints for Nexplanon: In the U.S., customers relying on federal and state-subsidized programs are facing constrained funding, which is affecting purchasing decisions for contraceptive products like Nexplanon.
Respiratory Portfolio Challenges: The respiratory portfolio has been under pressure due to a mild respiratory season in certain markets, impacting the General Medicines base business.
Foreign Exchange (FX) Risks: The weakening U.S. dollar has increased the translated U.S. dollar value of euro-denominated debt by approximately $250 million, posing financial risks.
Restructuring and Manufacturing Separation Costs: The company is incurring significant costs related to restructuring and manufacturing separation activities, estimated at $250 million to $300 million for 2025. These costs are expected to enable future efficiencies but are a current financial burden.
Tariff Uncertainty: Potential tariffs, especially from the EU on pharmaceuticals, could impact adjusted gross margins, although the company has incorporated some documented tariffs into its guidance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company raised its revenue guidance range by $100 million at the midpoint for 2025, reflecting favorable foreign exchange rates and operational performance. Full-year revenue is expected to remain flat compared to the prior year, with strong volume growth in the second half driven by Vtama, Emgality, biosimilars, and Nexplanon.
Adjusted EBITDA Margin: The company affirmed its adjusted EBITDA margin guidance range of 31% to 32% for 2025. Year-to-date adjusted EBITDA margin is 32.4%, with expectations for moderation in the second half due to investments in Vtama and R&D.
Free Cash Flow: The company expects to deliver more than $900 million of free cash flow before one-time costs in 2025, supported by operational efficiencies and lower interest expenses.
Debt Reduction: Organon aims to achieve a net leverage ratio below 4x by the end of 2025 and further reduce it to 3.5x or below by the end of 2026. The company repaid $350 million of principal on long-term debt in Q2 2025.
Women's Health and Fertility Business: The global fertility business is expected to deliver high single-digit growth in 2025, driven by geographical expansion and increased demand. Nexplanon is anticipated to continue global growth, with a 5-year duration indication launch planned for later in 2025.
Biosimilars: The biosimilars business is performing better than expected, with Hadlima generating $100 million year-to-date, up 68% year-over-year. The company plans to launch a portfolio of Henlius products, including a denosumab biosimilar, in late 2025.
Vtama: Vtama is expected to achieve 80% addressable population coverage in national and regional healthcare plans by early 2026. The product is positioned to drive significant revenue growth, particularly in the pediatric segment.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about incremental sales and marketing investment for Vtama, including DTC or sales force expansion, and remind us how many practitioners you are currently calling on and how many reps you currently have supporting the product?
A:In July, new telehealth and DTC campaigns were initiated, along with pediatric initiatives to penetrate the pediatric segment. Investments for the second half of the year are weighted towards this period. The company has expanded its sales force to over 125 reps in the field.
Q:Can you elaborate on the federal funding headwinds for Nexplanon in the U.S. and the extent to which the decline in U.S. Nexplanon sales this quarter is related to purchase timing versus underlying pressures?
A:The decline is due to a combination of factors, including effects on Planned Parenthood and Medicaid-related funding, as well as purchase timing. Despite these challenges, there is confidence in growth for Nexplanon this year, with positive developments like Title X unfreezing in key states such as California and Texas. The company expects to reach the $1 billion threshold and launch the 5-year indication by the end of the year.
Q:How do you expect your capital allocation priorities to change as you approach and exceed your leverage ratio targets?
A:The focus is currently on deleveraging, with principal debt payments already made. Further discussions on capital allocation priorities will occur once the leverage ratio falls below 3.5.
Q:What impact might the 15% EU tariff have on 2026 margins, and how should we think about free cash flow conversion and onetime items in 2026?
A:It is too early to speculate on the 2026 tariff impacts. The largest import exposure into the U.S. comes from the EU, accounting for approximately 2/3 of imported value. Free cash flow is expected to grow in line with the business, with onetime costs continuing to decline, leading to significant discretionary cash flow growth next year.
Q:How are you addressing the current Vtama volume data, and what steps are being taken to turn the trajectory around?
A:Investments in DTC and telehealth campaigns, sales force expansion, and pediatric segment penetration are underway. Access improvements and reduced reliance on coupon cards are expected to positively impact volume. The company aims to achieve 80% lives covered by Q1 next year, with gross-to-net improvements driving net revenue growth.
Q:What is driving the ramp in Vtama sales in the second half of the year to reach $150 million, and how much of that is driven by volume versus price?
A:The ramp is driven by DTC and telehealth campaigns, sales force expansion, and improved gross-to-net metrics. Contributions from Canada and Japan also play a role. The U.S. market is key, with significant progress in PBM additions and reduced coupon card reliance.
Q:How should we think about the impact of the 5-year Nexplanon indication on growth in 2026 and 2027, and what portion of current volumes are from implant replacements?
A:The 5-year indication will provide exclusivity through 2029 and open new segments, such as the family complete segment. While there may be a small headwind in 2026, the indication is expected to drive growth in subsequent years. Current volumes include a mix of new implants and replacements.
Q:Do you still expect to invest in the endometriosis space after the 6219 setback, and what is the status of the backup molecule?
A:The 6219 program and its backup molecule have been discontinued due to a lack of efficacy signal. The company will not pursue further investment in this mechanism.
Q:What are your expectations regarding the FDA's guidance for developing a generic Nexplanon, particularly with the 5-year approval?
A:The company is working with the FDA on labeling for the 5-year indication. The FDA will determine the guidance for generic manufacturers. The 5-year indication is expected to dominate the market, making it challenging for generics to coexist with a 3-year version.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the 2026 tariff impacts, stating it was too early to speculate. Additionally, they did not provide specific details on the portion of current Nexplanon volumes from implant replacements or the exact impact of the 5-year indication on growth in 2026 and 2027.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Arjona Ferreira
Co Research
Executive VP
Hadlima
Investor Relations
Nexplanon currency
Research Division
Tofidence
Vtama
Women Health
access objective
asset
base
biosimilars
care
conference
date
digit
franchise
goal
hospital
interest expense
leverage end
margin
measure
pillar
population
portfolio
postpartum hemorrhage
presentation
principal term
term debt
OGN Transcript
Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
Unknown2-12
The earnings call reveals several negative factors: declining revenue guidance, margin compression, and a net loss in Q4 2025. Despite growth in biosimilars and cost savings, these are overshadowed by underperformance in key areas like women's health and respiratory portfolio. Additionally, management's vague responses in the Q&A section, especially regarding the Audit Committee investigation, add uncertainty. The slight positive from biosimilars and cost savings isn't enough to outweigh these negatives, leading to an overall negative sentiment, likely resulting in a -2% to -8% stock price decline.
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neutral12-3
Organon & Co. (OGN) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call summary shows mixed signals: positive revenue guidance and debt reduction are offset by challenges in the respiratory segment and flat growth for Nexplanon. The Q&A highlights management's cautious outlook, especially regarding the CEO search and competitive pressures. Despite some positive developments, such as Vtama's growth potential, uncertainties around established brands and leadership changes create a balanced sentiment. Without market cap data, the overall prediction is neutral, reflecting both opportunities and risks.
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call shows strong financial performance with significant revenue growth in key products like Hadlima and Vtama. Despite slight margin declines, positive developments in market expansion and strategic investments, such as in DTC and telehealth campaigns, are promising. The Q&A highlights confidence in overcoming challenges, with plans for growth and deleveraging. No negative guidance or major concerns were raised, and the optimistic outlook on product expansions and sales strategies suggests a likely positive stock price reaction in the short term.
OGN Slides
OGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
